Introduction
============

Despite considerable progress in cancer diagnosis and treatment, 18.1 million new cancer cases were detected and 9.6 million cancer-associated deaths occurred worldwide in 2018 ([@b1-ol-0-0-11648]). The therapeutic strategies for treating numerous types of cancer are usually ineffective, primarily due to the lack of specific diagnostic and prognostic markers ([@b2-ol-0-0-11648]). Diagnostic biomarkers could be used for screening or early detection of cancer, while prognostic biomarkers could be used to predict the likelihood of recurrence or progression in patients with cancer ([@b2-ol-0-0-11648]). Accordingly, it is necessary to identify novel biomarkers for potential clinical applications ([@b3-ol-0-0-11648]--[@b5-ol-0-0-11648]).

Long non-coding RNAs (lncRNAs) have crucial roles in the progression of cancer ([@b6-ol-0-0-11648]--[@b10-ol-0-0-11648]). Certain lncRNAs are involved in the modulation of neoplastic proliferation, invasion and metastasis. In addition, several studies have indicated that lncRNAs may serve as potential cancer-specific biomarkers ([@b2-ol-0-0-11648],[@b11-ol-0-0-11648]--[@b13-ol-0-0-11648]).

The gene encoding long intergenic non-protein-coding RNA 1614 (LINC01614), also known as lung cancer-associated lncRNA 4, is located on chromosome 2q35 in between two exons and was originally identified as being upregulated in lung cancer ([@b14-ol-0-0-11648]). In addition, Liu *et al* ([@b15-ol-0-0-11648]) reported that LINC01614 knockdown inhibits cell proliferation through the microRNA (miR)-217/forkhead box (FOX)P1 axis in lung adenocarcinoma. Another study indicated that LINC01614 is highly expressed in breast cancer tissue and associated with poor prognosis based on the data from The Cancer Genome Atlas (TCGA) ([@b16-ol-0-0-11648]). Increasing evidence has indicated that LINC01614 may act as an oncogene and serve as a biomarker in several types of cancer ([@b15-ol-0-0-11648]--[@b18-ol-0-0-11648]). However, beyond the limited information provided by these studies, the role of LINC01614 in malignant tumors has remained elusive.

In the present study, a comprehensive pan-cancer analysis of the data available from public databases was performed to determine the correlation between LINC01614 expression and the prognoses of various malignancies. In addition, bioinformatics analyses were performed to identify the physiological functions of this lncRNA to clarify its potential role as an oncogene. Furthermore, the expression levels in paired normal and tumor tissue specimens from patients with non-small cell lung cancer (NSCLC) or colon cancer were assessed to validate the results.

Materials and methods
=====================

### Malignancy-associated microarray and RNA sequencing data in the Gene Expression Omnibus (GEO) and TCGA databases

Microarray and RNA sequencing data on LINC01614 expression were systematically searched in the GEO database on 26th June 2019 (<http://www.ncbi.nlm.nih.gov/geo/>). The search terms were as follows: (neoplasm OR cancer OR tumor OR carcinoma) AND (lncRNA OR long non-coding RNA). The inclusion criteria were as follows: i) Expression data for LINC01614 were provided or it was possible to calculate them for each sample; ii) samples in each dataset included cancer tissues and normal tissues or cancer tissues with prognostic information; iii) the number of samples in each dataset was \>20; and iv) the species in each dataset was *Homo sapiens*. Samples based on cell lines were excluded. Gene expression matrices were downloaded from the GEO database and extracted using R and associated packages.

Datasets including RNA sequencing and clinical data for 24 types of cancer from TCGA were downloaded and extracted using the TCGA biolinks package (<https://gdc-portal.nci.nih.gov/>). RNA sequencing (RNA-seq) expression data were normalized using RNA-seq by Expectation-Maximization ([@b19-ol-0-0-11648]).

### Comparison of LINC01614 expression in normal and tumor tissues

LINC01614 expression in normal tissues was examined from the RNA-seq data obtained from the Genotype-Tissue Expression (GTEx) (<https://www.gtexportal.org/home/>) database, comprising \~11,600 samples from 53 tissue types. The pre-processed data were downloaded from the portal and converted to the units of transcripts per million (TPM) for comparison of relative expression levels among different tissues. The RNA-seq data from TCGA for libraries with sufficient malignant and adjacent normal tissues were also used to evaluate the expression of LINC01614 in malignancies. The RNA-seq expression matrices of these datasets were normalized by log2(x+1) transformation. The relative expression levels were statistically compared between the tumor tissues and adjacent normal tissues using unpaired Student\'s t-tests.

### Receiver operating characteristic (ROC) and summary ROC (SROC) curve analysis

Datasets with sufficient malignant and adjacent normal tissues were used to evaluate the diagnostic value of LINC01614 in malignancies. ROC curve analysis was performed to evaluate the area under the curve (AUC) with 95% CIs, sensitivities and specificities for each dataset. SROC curve analysis was performed using Stata 14.2 (StataCorp LLC) to demonstrate pooled sensitivity, pooled specificity and obtain the pooled AUC. I^2^ and Q tests were used to assess the heterogeneity of this meta-analysis. Meta-regression analysis was performed to determine the potential cause of heterogeneity. Deeks\' funnel plots were used to evaluate the potential publication bias of the SROC analysis.

### Survival analysis and comprehensive meta-analysis

The above-mentioned GEO data with survival information and TCGA data were used to assess the prognostic value of LINC01614. Samples in each dataset were divided into two groups according to the cut-off value determined from ROC curves ([@b20-ol-0-0-11648]). Univariate Cox regression analysis was performed to obtain hazard ratios (HRs) with 95% CIs for overall survival (OS). Pooled HRs and 95% CIs were combined to assess the association between LINC01614 expression and prognosis in various malignancies. If the 95% CI of the combined HR did not overlap with 1, the results were considered significant. If I^2^\>50% or P≤0.05, the heterogeneity was considered significant and a random-effects model was chosen; if not, a fixed-effects model was used. A sensitivity analysis was also performed to assess the stability of the combined results and a subgroup analysis was performed to detect possible sources of heterogeneity. Begg\'s test and the trim fill method were used to assess the potential publication bias.

### Tissue samples and clinical data collection

For validation of the RNA-seq data, 74 and 78 tumor tissue samples (alongside matched adjacent normal tissue samples) from patients with non-small cell lung cancer (NSCLC) or colon cancer, respectively, who underwent resection at Beijing Tongren Hospital (Beijing, China) between October 2016 and March 2018, were analyzed. The tissue samples were immersed in RNA later (Ambion) and stored at −80°C until use. The clinicopathological characteristics of each patient were obtained from their medical records. The study was approved by the ethics committee of Beijing Tongren Hospital (Beijing, China).

### RNA extraction and RT-qPCR

Total RNA was extracted from the tissue samples with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The RNA integrity was detected using 1% agarose gel electrophoresis and a spectrophotometer was used to measure its concentration and purity. The 28S:18S ribosomal RNA ratio of RNA samples was required to be \~2:1; the A260/A280 ratios were 1.8--2.2 and the absorbance at 260 nm (A260)/A230 ratios were required to be \>1.7 for the RNA samples to be considered qualified. RNA was used to synthesize cDNA using the SuperScript III Reverse Transcriptase kit (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol; the mixture included 1 µg total RNA, 1 µl oligo(dT)~20~, 1 µl dNTP Mix, 1 µl 0.1M DTT, 1 µl RNaseOUT, 1 µl SuperScript™ III RT and enzyme-free water in a 20 µl reaction volume. The reaction conditions used were 50°C for 60 min and 70°C for 15 min. Reverse transcription-quantitative (RT-q)PCR was performed using the SYBR-Green Mix (Takara Bio, Inc.) on an ABI 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used for qPCR: Pre-denaturation at 94°C for 2 min, 40 cycles of denaturation at 94°C for 5 sec and annealing at 60°C for 30 sec, and a final extension step at 72°C for 10 min. The expression levels were normalized to those of GAPDH mRNA ([@b16-ol-0-0-11648]) using the 2^−Δ∆Cq^ method ([@b21-ol-0-0-11648]), where ∆Cq=(Cq of the target-Cq GAPDH) and ∆∆Cq=∆Cq tumor tissues - ∆Cq adjacent non-tumor tissues. Each sample was analyzed in triplicate. The sequences of the primers used in the study were as follows: LINC01614 forward, 5′-GGGACTTCAGACACGGAGAA-3′ and reverse, 5′-GGACACAGACCCTAGCACTT-3′; collagen XI α1 chain (COL11A1) forward, 5′-TAACATCGCTGACGGGAAGTG-3′ and reverse, 5′-CCGTGATTCCATTGGTATCAACA-3′; secreted protein acidic and cysteine rich (SPARC) forward, 5′-CCCATTGGCGAGTTTGAGAAG-3′ and reverse, 5′-CAAGGCCCGATGTAGTCCA-3′; periostin (POSTN) forward, 5′-CAACGGGCAAATACTGGAAAC-3′ and reverse, 5′-TCTCGCGGAATATGTGAATCG-3′; COL5A2 forward, 5′-ACAGGGTTTACAAGGACAGCA-3′ and reverse, 5′-GGTCCAGGATCACCAGGTT-3′; fibroblast activation protein α (FAP) forward, 5′-TCAGCTATGATGCCATTTCG-3′ and reverse, 5′-CCTCCCACTTGCCACTTGTA-3′; and GAPDH forward, 5′-CAACTCCCTCAAGATTGTCAGCAA-3′ and reverse, 5′-GGCATGGACTGTGGTCATGA-3′.

### Bioinformatics analysis of LINC01614

To investigate the molecular pathways associated with the upregulation of LINC01614 in malignancies, gene set enrichment analysis (GSEA) was performed using the GSEA software 3.0 (<http://software.broadinstitute.org/gsea/msigdb/index.jsp>) ([@b22-ol-0-0-11648]). Annotated gene sets 'c2.cp.kegg.v6.2.symbols.gmt' and 'h.all.v6.2.symbols.gmt' were downloaded from the Molecular Signatures Database ([@b23-ol-0-0-11648]). The normalized enrichment score was determined by the analysis of 1,000 permutations. A gene set was considered significantly enriched when the false discovery rate was \<0.25. In addition, Pearson\'s correlation coefficient was determined to identify the genes co-expressed with LINC01614. Genes with Pearson\'s r-values \>0.3 and P\<0.01 were considered significant.

### Statistical analysis

Microarray and RNA-seq data were analyzed using R, version 3.5.2, and associated packages. An unpaired Student\'s t-test, the χ^2^ test, ROC curve analysis and univariate Cox regression analysis were performed using SPSS Statistics v22.0 (IBM Corp.). Diagnostic and prognostic meta-analyses were conducted using Stata 14.2 (StataCorp LLC). The measurement data were expressed as the mean ± SD. Student\'s t-test and the χ^2^ test were used to analyze the significance of differences between groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### LINC01614 expression is high in most tumor tissues but low in most normal tissues

To determine the general distribution of LINC01614 in normal tissues, its expression was first examined across 53 different tissues in the GTEx database. As presented in [Fig. 1](#f1-ol-0-0-11648){ref-type="fig"}, the median expression levels of LINC01614 in different tissue types ranged from a TPM of 0 (vagina) to 5.213 (cultured fibroblasts). Except for the cultured fibroblasts (median TPM=5.213), coronary artery (median TPM=1.496), tibial artery (median TPM=1.012) and aorta (median TPM=1.009), all of which exhibited relatively high levels of LINC01614, most of the other tissues had low levels (median TPM \<0.5).

After excluding the datasets that had an insufficient amount of normal tissue samples, 18 types of cancers with 7,043 samples from TCGA were selected to evaluate the expression patterns of LINC01614 in cancers. As presented in [Fig. 2](#f2-ol-0-0-11648){ref-type="fig"}, most tumors (16 of them) had higher LINC01614 levels than the normal tissues. Unpaired Student\'s t-tests indicated that LINC01614 was significantly upregulated in 15 types of malignant tissues, including bladder carcinoma (BLCA), breast invasive carcinoma (BRCA), cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD) and thyroid carcinoma (P\<0.05). Furthermore, the expression levels of LINC01614 were relatively low in malignant prostate adenocarcinoma (PRAD) and uterine corpus endometrial carcinoma (UCEC) tissues but not significantly different from the levels in the adjacent normal tissues (P\>0.05). Other normal tissue types had low levels of LINC01614 when it was highly expressed in the adjacent tumor tissues.

### LINC01614 may serve as a diagnostic predictor based on GEO and TCGA databases

In total, 590 datasets were identified during the primary search, among which 39 were downloaded later from the GEO database after relevant assessments and evaluations. Eventually, eight datasets were included in the analysis (GSE70880, GSE115856, GSE61763, GSE103909, GSE104836, GSE115018, GSE53622 and GSE53624) after screening in accordance with the inclusion criteria. Finally, after excluding the datasets that had an insufficient amount of normal tissue samples, 24 datasets, including 7,320 patients, from GEO and TCGA databases were used to assess the diagnostic predictive ability of LINC01614. The AUCs, sensitivities and specificities of these datasets are presented in [Table I](#tI-ol-0-0-11648){ref-type="table"}. The results revealed that P\<0.05 for the ROC curve in 20/27 cohorts, which indicated that LINC01614 was a suitable diagnostic marker for numerous human malignancies. The combined sensitivities and specificities of LINC01614 for the diagnosis of malignancies are presented in [Fig. 3](#f3-ol-0-0-11648){ref-type="fig"}. Subsequently, the SROC curve analysis was performed to determine the diagnostic value of LINC01614 in malignancies. The combined sensitivity, specificity and AUC of the SROC curve were 0.80 (95% CI, 0.71--0.86), 0.85 (95% CI, 0.77--0.90) and 0.89 (95% CI, 0.86--0.92), respectively ([Fig. 3A and C](#f3-ol-0-0-11648){ref-type="fig"}). The combined results indicated that LINC01614 was suitable to diagnose human malignancies, even though there was a marked heterogeneity among the results. Deeks\' funnel plots indicated that there was no significant publication bias in the SROC curve analysis (P=0.22; [Fig. 3D](#f3-ol-0-0-11648){ref-type="fig"}). Thus, a meta-regression analysis was performed to determine the cause of heterogeneity. The results indicated that cancers of the reproductive (P\<0.001) and urinary system (P=0.01) may be a major cause of heterogeneity ([Fig. 3B](#f3-ol-0-0-11648){ref-type="fig"}). Of note, UCEC, KICH and PRAD, which exhibited no significant differences in LINC0164 expression between tumor and normal tissues, are all cancers of the reproductive or urinary system. Therefore, these results indicated that except for certain cancers of these systems, LINC01614 may be a potential diagnostic biomarker for the majority of malignancies.

### Prognostic value of LINC01614 for OS in malignancies

In total, 23 TCGA and two GEO datasets (8,213 patients) were included to analyze the association between LINC01614 expression and survival in human cancers. The HR and 95% CI of each dataset were obtained by univariate Cox regression model analysis ([Table II](#tII-ol-0-0-11648){ref-type="table"}). As shown in [Fig. 4](#f4-ol-0-0-11648){ref-type="fig"}, the pooled HR from all the datasets indicated a significant association between high LINC01614 expression and poor OS in various malignant tumors (HR=1.479; 95% CI, 1.355--1.614; P\<0.001). To assess the stability of the combined results, a sensitivity analysis of OS was performed. The results of the sensitivity analysis suggested that no individual study changed the combined results; thus, the pooled results were reliable ([Fig. 4C](#f4-ol-0-0-11648){ref-type="fig"}). Publication bias was assessed by Begg\'s test and the results suggested that there was a considerable publication bias in this meta-analysis (P=0.001; [Fig. 5A](#f5-ol-0-0-11648){ref-type="fig"}). To further verify the reliability of the results, a trim and fill analysis was performed to eliminate the impact of publication bias by establishing symmetry assumptions ([@b24-ol-0-0-11648]). As indicated by the filled funnel plots in [Fig. 5B](#f5-ol-0-0-11648){ref-type="fig"}, six assumed studies were filled to eliminate the publication bias. After adjusting for filling assumed studies, the adjusted HR and 95% CI (1.414 and 1.299--1.539, respectively) was not significantly different compared with the initial HR and 95% CI (1.479 and 1.355--1.614, respectively), confirming that the results were reliable.

To assess potential heterogeneity, a subgroup analysis of OS was performed based on different organ systems. The results suggested that upregulation of LINC01614 was significantly associated with poor OS in malignancies from most organ systems, including the digestive (P\<0.001), urinary (P\<0.001), nervous (P=0.009), respiratory (P=0.002) and endocrine (P=0.002) systems, in addition to the malignancies involving head and neck (P=0.043), breast (P=0.031) and soft tissue (P\<0.001), whereas there was no association with cancers from the reproductive system (P=0.396) or skin (P=0.183) ([Table III](#tIII-ol-0-0-11648){ref-type="table"} and [Fig. 4B](#f4-ol-0-0-11648){ref-type="fig"}). Of note, only cancers of the urinary system had significant heterogeneity within the subgroup, suggesting that LINC01614 has distinct roles in these four different urinary cancers. LINC01614 may be an oncogene and prognostic marker for BLCA or KIRP, but not for KICH or KIRC.

### Bioinformatics analysis identified LINC01614-associated signaling pathways in human cancers

To identify the possible LINC01614-associated signaling pathways in human cancers, GSEA was performed on eight TCGA datasets with a weight of prognostic analyses of \>5, including BLCA, BRCA, HNSC, KIRC, LUAD, LUSC, skin cutaneous melanoma and STAD. To eliminate the effects of tissue specificity, the intersection between these GSEA results from different datasets was used. As illustrated in [Figs. 6](#f6-ol-0-0-11648){ref-type="fig"}, [7](#f7-ol-0-0-11648){ref-type="fig"} and [S1](#SD1-ol-0-0-11648){ref-type="supplementary-material"}--[7](#SD1-ol-0-0-11648){ref-type="supplementary-material"}, and [Tables SI](#SD1-ol-0-0-11648){ref-type="supplementary-material"}--[IX](#SD1-ol-0-0-11648){ref-type="supplementary-material"}, the GSEA enrichment plots indicated that LINC01614 expression was highly associated with the epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) receptor interaction, focal adhesion, gap junction, adherens junction and cell adhesion molecules. Furthermore, LINC01614 expression was associated with angiogenesis, apoptosis, KRAS signaling, transforming growth factor-β (TGF-β) signaling, tumor necrosis factor-α (TNF-α) signaling, mitogen-activated protein kinase (MAPK) signaling, Wnt signaling and various cancer-associated signaling pathways.

Pearson\'s correlation coefficient was then used to evaluate the genes that were co-expressed with LINC01614 in these TCGA datasets. To obtain the most significantly co-expressed genes, the overlapping results of eight different datasets (Pearson\'s r\>0.3, P\<0.01) were obtained. As illustrated in [Fig. 8](#f8-ol-0-0-11648){ref-type="fig"}, 36 genes were significantly co-expressed with LINC01614 and 32 of these genes were associated with EMT. Based on the biological roles of LINC01614 in cancers, it was concluded that LINC01614 mainly has an important role in EMT and associated signaling pathways in malignancies.

### RT-qPCR validation of LINC01614 and co-expressed gene levels in cancer tissues

To confirm the reliability and validity of the public RNA-seq data, the expression profiles of LINC01614 and five significantly co-expressed genes, including COL11A1, FAP, POSTN, SPARC and COL5A2, were analyzed using RT-qPCR in paired samples from 74 patients with NSCLC and 78 patients with colon cancer. The results indicated that LINC01614 was expressed at a significantly higher level in NSCLC and colon cancer tumor tissues than their respective adjacent normal tissues ([Fig. 9A and B](#f9-ol-0-0-11648){ref-type="fig"}). The diagnostic accuracies of LINC01614 for NSCLC and colon cancer were investigated by ROC analyses, which indicated a sensitivity, specificity and AUC of 0.743, 0.905 and 0.868 for NSCLC (cutoff value =1.287) and of 0.795, 0.923 and 0.876 for colon cancer (cutoff value =0.625), respectively ([Fig. 9C and D](#f9-ol-0-0-11648){ref-type="fig"}). Further analysis of the association between LINC01614 and clinicopathological characteristics in the cohorts of the present study suggested that higher LINC01614 expression was significantly associated with tumor size, lymph node metastasis and TNM stage in patients with NSCLC, and with lymph node metastasis and TNM stage in patients with colon cancer ([Tables IV](#tIV-ol-0-0-11648){ref-type="table"} and [V](#tV-ol-0-0-11648){ref-type="table"}). These results indicated that the expression of LINC01614 was higher in NSCLC and colon cancer tissues and may function as an oncogene in these cancers.

Furthermore, Pearson\'s correlation analysis between LINC01614 and co-expressed genes, including COL11A1, FAP, POSTN, SPARC and COL5A2 in NSCLC and colon cancer tissues, was performed. The results indicated that the expression of LINC01614 was markedly positively correlated with the levels of COL11A1, FAP, POSTN, SPARC, and COL5A2 in NSCLC and colon cancer ([Figs. 10](#f10-ol-0-0-11648){ref-type="fig"} and [11](#f11-ol-0-0-11648){ref-type="fig"}). These results were in line with those of the comprehensive bioinformatics analyses described above, demonstrating the credibility of the RNA-seq data.

Discussion
==========

lncRNAs act as crucial regulators of almost all aspects of physiological and pathological processes ([@b25-ol-0-0-11648]--[@b28-ol-0-0-11648]). Accumulating evidence indicates that lncRNAs contribute to the carcinogenesis and progression of various cancers ([@b6-ol-0-0-11648]--[@b10-ol-0-0-11648]). LINC01614 was initially reported as an upregulated lncRNA in lung cancer ([@b14-ol-0-0-11648]). Further studies demonstrated that LINC01614 promotes the progression of lung adenocarcinoma by competing with miR-217 and preventing the miR-217/FOXP1 interaction ([@b15-ol-0-0-11648]). Dysregulation of LINC01614 expression has also been reported in breast carcinoma and indicated to be associated with poor prognosis ([@b16-ol-0-0-11648]). Emerging evidence suggests that LINC01614 acts as an oncogene and may be a potential biomarker in malignancies. However, its expression and clinical implication in a full spectrum of cancers have remained to be determined. To the best of our knowledge, the present study was the first to comprehensively assess the role of LINC01614 in cancer. Owing to the continuous development of high-throughput sequencing, abundant high-throughput data from human cancers have been collected in public databases. The public data in these databases have increasingly crucial roles in the study of cancers ([@b29-ol-0-0-11648]). Based on large-sample high-throughput data from public databases, the present study aimed to investigate the diagnostic and prognostic value of LINC01614 in malignancies.

In the present study, comprehensive analyses across 53 normal tissue types and 24 tumor types were performed, including data mining, differential expression analyses, ROC and SROC analyses, survival analyses, meta-analyses and bioinformatics analyses. Overall, the results suggested that the majority of normal tissues have a low expression of LINC01614. Statistical analysis (t-tests) further revealed that LINC01614 was significantly upregulated in 15 of the 18 types of malignant tissues compared with the expression levels in their normal tissues. Furthermore, ROC and SROC curve analyses indicated that LINC01614 is of suitable diagnostic value in various malignancies. However, meta-regression analysis revealed that cancers of the reproductive system and urinary system contributed to the significant heterogeneity of the SROC curve analysis. In line with this result, UCEC, KICH and PRAD, which are cancers of the reproductive or urinary system, exhibited no significant alterations between tumor and normal tissues. Therefore, except for several cancers of these systems, LINC01614 was significantly upregulated in malignant tissue samples and may be a potential diagnostic biomarker for the majority of malignancies, including cancers of the digestive, respiratory, nervous and endocrine systems, in addition to the malignancies of the breast and head and neck.

In addition, a meta-analysis was performed to determine the prognostic predictive capacity of LINC01614 in cancers. The pooled results indicated that upregulation of LINC01614 was significantly associated with poor OS in malignant tumors from most organ systems, including the digestive, urinary, nervous, respiratory and endocrine systems, as well as of the head and neck, breast and soft tissue with the exception of cancers of the reproductive system or skin. In addition, only cancers of the urinary system caused significant heterogeneity in this subgroup.

Overall, abnormal expression of LINC01614 and its associations with clinical outcome were highly cancer-dependent. LINC01614 had no reliable diagnostic or prognostic value in some cancers of the reproductive or urinary system. However, for cancers of the digestive system, respiratory system, breast, head and neck, nervous system and endocrine system, LINC01614 was proved to be an oncogene and credible biomarker with diagnostic and prognostic value.

The results of the RT-qPCR validation also indicated that the expression of LINC01614 was higher in NSCLC and colon cancer tissues compared with the expression levels in their respective adjacent normal tissues; high LINC01614 expression was associated with lymph node metastasis and tumor stage, further supporting its role as an oncogene in these cancers. In addition, 9 of the 78 colon cancer patients had liver metastasis. In this cohort, there were more patients with liver metastasis in the high-expression group (7 of 38) than in the low-expression group (2 of 38), but the difference was not statistically significant (P=0.069). This insignificant difference may be due to the limited sample size. LINC01614 is able to promote liver and lymph node metastases in colon cancer. These validation results demonstrated that the comprehensive analyses were reliable.

At present, the molecular mechanisms of LINC01614 in cancers remain to be fully elucidated. Therefore, bioinformatics analyses were performed to discover the inherent molecular mechanisms of LINC01614. The results indicated that LINC01614 may have important effects on the progression of cancers by modulating several cellular biology processes, including the EMT, ECM receptor interaction, focal adhesion, gap junction, angiogenesis, apoptosis, KRAS signaling, TGF-β signaling, TNF-α signaling and various cancer-associated signaling pathways. Furthermore, most of the genes identified to be co-expressed with LINC01614 were associated with EMT in human cancers. Positive correlations between LINC01614 and five co-expressed genes, including COL11A1, FAP, POSTN, SPARC and COL5A2, were identified in NSCLC and colon cancer tissues. Relevant studies have revealed that COL11A1 and COL5A2 are important EMT mediators and are involved in tumorigenesis and metastasis of several cancers ([@b30-ol-0-0-11648]--[@b33-ol-0-0-11648]). According to previous studies, FAP derived from cancer-associated fibroblasts was able to be induced by EMT through Wnt/β-catenin signaling ([@b34-ol-0-0-11648],[@b35-ol-0-0-11648]). Overexpression of POSTN was able to induce EMT through the MAPK/ERK pathway ([@b36-ol-0-0-11648],[@b37-ol-0-0-11648]). Furthermore, SPARC was able to increase the migration and invasion of cancer cells by promoting EMT through the phosphorylated (p)-FAK/p-ERK pathway ([@b38-ol-0-0-11648],[@b39-ol-0-0-11648]). These results suggested that LINC01614 may be involved in EMT and associated signaling pathways to influence the progression of human cancers.

During EMT, cells lose their epithelial properties, generating migratory mesenchymal cell types with highly invasive characteristics ([@b40-ol-0-0-11648]--[@b42-ol-0-0-11648]). In addition, cancer cells undergoing EMT exhibit increased robustness including inhibition of apoptosis and senescence, and acquisition of immunosuppression and drug resistance ([@b43-ol-0-0-11648],[@b44-ol-0-0-11648]). Metastasis is the major cause of mortality in patients with cancer, and cancer cells that obtain invasive characteristics through EMT have a crucial role during metastasis ([@b45-ol-0-0-11648]--[@b47-ol-0-0-11648]). The present bioinformatics analyses revealed that a high level of LINC01614 may be involved in EMT and associated signaling pathways to influence cancer progression and metastasis. In line with this, RT-qPCR validation also suggested that high LINC01614 expression was associated with lymph node metastasis and tumor staging in colon cancer and NSCLC. This observation may be attributed to the influence of LINC01614 on the EMT. The positive correlation between LINC01614 and EMT-associated genes, including COL11A1, FAP, POSTN, SPARC and COL5A2, also confirmed this biological process. Further studies are required to validate the molecular mechanisms whereby LINC01614 modulates EMT in malignancies.

There are numerous strengths to the present study. First, it was a pan-cancer comprehensive analysis, including 53 normal tissue types and 32 cancer datasets with data from 9,091 patients, representing a complete dataset available for LINC01614 in human cancers. These large-sample data from different databases were able to enhance the reliability of this comprehensive analysis. Furthermore, the reliability and validity of the results of the comprehensive analysis were confirmed with a molecular biology technique with clinical samples obtained at our hospital. Finally, the results of the bioinformatics analyses were validated in eight cancer datasets. The rigorous evaluation criteria further supported the reliability and repeatability of the results.

However, the study also has certain limitations. First, significant heterogeneity existed in certain analyses in this study. The heterogeneity was derived from cancers originating from certain specific tissues that were validated by meta-regression and subgroup analyses. Furthermore, the diagnostic value of LINC01614 was identified in fresh solid tissues, but the early diagnostic value requires to be validated using the blood samples of cancer patients. In addition, due to the limited sample size, the association between LINC01614 and certain clinicopathological characteristics may be false-negative, including liver metastasis in colon cancer, and this requires further investigation with larger sample sizes and multicenter research. Finally, the molecular mechanisms of LINC01614 were not identified by this approach. Accordingly, further targeted studies are required to verify these results.

In summary, LINC01614 emerged as an oncogene in most malignancies, and its abnormal expression and clinical outcome associations were highly cancer-dependent. For cancers of the digestive system, respiratory system, breast, head and neck, nervous system and endocrine system, LINC01614 is a credible biomarker with diagnostic and prognostic value. However, for certain cancers of the reproductive and urinary system, LINC01614 had no significant clinical association. Furthermore, bioinformatics analysis indicated that LINC01614 may promote the progression and metastasis of malignancies by modulating the EMT in most malignancies. For future clinical applications, comprehensive studies are required to assess the detailed molecular mechanisms underlying the oncogenic role of LINC01614.
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![Expression of long intergenic non-coding RNA 1614 in malignancies based on The Cancer Genome Atlas data. Significance was determined using an unpaired Student\'s t-test. Values are expressed as the mean ± SD. \*P\<0.05. RSEM, RNA-sequencing Expectation-Maximization; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.](ol-20-02-1383-g01){#f2-ol-0-0-11648}

![(A) Combined sensitivity and specificity of long intergenic non-coding RNA 1614 for the diagnosis of malignancies. (B) Meta-regression analysis indicated that reproductive system cancers (P\<0.001) and urinary system cancers (P=0.01) may be the major causes of heterogeneity. (C) SROC curve and (D) Deeks\' funnel plot analyses. The numbers in the circles represent the number of each study in [Table I](#tI-ol-0-0-11648){ref-type="table"}. The overall diagnostic efficiency was summarized by the regression curve. SROC, summary receiver operating characteristic; AUC, area under curve; TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; CRC, colorectal cancer; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; GC, gastric cancer; HCC, hepatocellular cancer; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LC, lung cancer; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; SENS, sensitivity; SPEC, specificity; ESS, explained sum of square.](ol-20-02-1383-g02){#f3-ol-0-0-11648}

![(A) Forest plots for the association between LINC01614 expression and OS. (B) Forest plots of subgroup analysis for OS. (C) Sensitivity analysis of datasets to evaluate the associations between LINC01614 expression and OS. LINC01614, long intergenic non-coding RNA 1614; OS, overall survival; TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma.](ol-20-02-1383-g03){#f4-ol-0-0-11648}

![(A) Begg\'s funnel plot for publication bias analysis of overall survival. (B) After adjusting for filling six assumed studies, the adjusted HR and 95% CI exhibited no significant changes compared with the initial HR and 95% CI. The assumed studies were indicated by small boxes. OR, odds ratio; s.e., standard error.](ol-20-02-1383-g04){#f5-ol-0-0-11648}

![Gene set enrichment analysis of signaling pathways based on The Cancer Genome Atlas - head and neck squamous cell carcinoma datasets. Enrichment plots for (A) the hallmark epithelial-mesenchymal transition, (B) KEGG-ECM receptor interaction; (C) KEGG focal adhesion, (D) the hallmark apical junction, (E) the hallmark KRAS signaling upregulated and (F) KEGG TGF-β signaling pathway. KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; TGF, transforming growth factor.](ol-20-02-1383-g05){#f6-ol-0-0-11648}

![Heatmap of gene set enrichment analysis data, indicating the association of long intergenic non-coding RNA 1614 expression with various signaling pathways in all the eight datasets. KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; TGF, transforming growth factor; TNF, tumor necrosis factor; MAPK, mitogen-activated protein kinase; CAMs, cell adhesin molecules; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma.](ol-20-02-1383-g06){#f7-ol-0-0-11648}

![Association of genes co-expressed with LINC01614 during epithelial to mesenchymal transition based on the overlapping results from the eight The Cancer Genome Atlas datasets. The sizes of the nodes represent the mean values of Pearson\'s correlation coefficients among the eight datasets. LINC01614, long intergenic non-coding RNA 1614; TGF, transforming growth factor; ADAM12, ADAM metallopeptidase domain 12; BGN, biglycan; CALU, calumenin; CDH11, cadherin 11; CERCAM, cerebral endothelial cell adhesion molecule; COL11A1, collagen XI α1 chain; COL12A1, collagen type XII α1 chain; COL1A1, collagen type I α1 chain; COL1A2, collagen type I α2 chain; COL3A1, collagen type III α1 chain; COL4A1, collagen type IV α1 chain; COL5A1, collagen type V α1 chain; COL5A2, collagen type V α2 chain; COL5A3, collagen type V α3 chain; COL6A2, collagen type VI α2 chain; COL6A3, collagen type VI α3 chain; COL8A2, collagen type VIII α2 chain; COMP, cartilage oligomeric matrix protein; CTHRC1, collagen triple helix repeat containing 1; DCN, decorin; DPYSL3, dihydropyrimidinase like 3; ECM2, extracellular matrix protein 2; FAP, fibroblast activation protein α; FBN1, fibrillin 1; FERMT2, fermitin family member 2; FN1, fibronectin 1; GAS1, growth arrest specific 1; GFPT2, glutamine-fructose-6-phosphate transaminase 2; GREM1, gremlin 1; HTRA1, HtrA serine peptidase 1; ITGBL1, integrin subunit β like 1; LGALS1, galectin 1; LOX, lysyl oxidase; LRP1, LDL receptor related protein 1; LRRC15, leucine rich repeat containing 15; LUM, lumican; MMP, matrix metallopeptidase; MXRA5, matrix remodeling associated 5; NID2, nidogen 2; NTM, neurotrimin; PDGFRB, platelet-derived growth factor receptor β; POSTN, periostin; PRRX1, paired related homeobox 1; RAB31, member RAS oncogene family; SFRP4, secreted frizzled related protein 4; SPARC, secreted protein acidic and cysteine rich; THBS2, thrombospondin 2; THY1, Thy-1 cell surface antigen; TIMP2, TIMP metallopeptidase inhibitor 2; TPM4, tropomyosin 4; VCAN, versican.](ol-20-02-1383-g07){#f8-ol-0-0-11648}

![Expression of LINC01614 in (A) NSCLC and (B) colon cancer determined by RT-qPCR. Receiver operating characteristic curve analyses based on the RT-qPCR results for (C) NSCLC and (D) colon cancer. \*\*P\<0.01. LINC01614, long intergenic non-coding RNA 1614; NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative PCR.](ol-20-02-1383-g08){#f9-ol-0-0-11648}

![Expression and Pearson\'s correlation analysis between LINC01614 and (A) COL11A1, (B) FAP, (C) POSTN, (D) SPARC and (E) COL5A2 in NSCLC. \*\*P\<0.01. ns, not significant; LINC01614, long intergenic non-coding RNA 1614; NSCLC, non-small cell lung cancer; COL11A1, collagen XI α1 chain; FAP, fibroblast activation protein α; POSTN, periostin; SPARC, secreted protein acidic and cysteine rich.](ol-20-02-1383-g09){#f10-ol-0-0-11648}

![Expression and Pearson\'s correlation analysis between LINC01614 and COL11A1 (A) FAP (B) POSTN (C) SPARC (D) and COL5A2 (E) in colon cancer. \*P\<0.05; \*\*P\<0.01. LINC01614, long intergenic non-coding RNA 1614; COL11A1, collagen XI α1 chain; FAP, fibroblast activation protein α; POSTN, periostin; SPARC, secreted protein acidic and cysteine rich.](ol-20-02-1383-g10){#f11-ol-0-0-11648}

###### 

Study characteristics in ROC and SROC curve analyses.

  No.   Study         AUC (95% CI)           P-value   Tumor tissue samples   Normal tissue samples   Cut-off value   TP     FP   FN    TN   Tumor type   Detection method
  ----- ------------- ---------------------- --------- ---------------------- ----------------------- --------------- ------ ---- ----- ---- ------------ ------------------
  1     GSE103909     0.852 (0.670--1.000)   0.007     9                      12                      −2.025          8      3    1     9    CHOL         Microarray
  2     GSE104836     0.990 (0.962--1.000)   \<0.001   10                     10                      0.049           10     1    0     9    CRC          RNA-seq
  3     GSE115018     0.604 (0.359--0.850)   0.386     12                     12                      −2.494          7      3    5     9    HCC          Microarray
  4     GSE115856     0.520 (0.290--0.750)   0.852     15                     15                      3.332           6      1    9     14   CRC          Microarray
  5     GSE61763      0.520 (0.295--0.745)   0.852     15                     15                      3.526           6      2    9     13   RCC          Microarray
  6     GSE70880CRC   0.903 (0.808--0.997)   \<0.001   20                     20                      6.148           16     2    4     18   CRC          Microarray
  7     GSE70880GC    0.815 (0.673--0.957)   0.001     20                     20                      4.981           15     3    5     17   GC           Microarray
  8     GSE70880HCC   0.714 (0.533--0.897)   0.038     16                     16                      6.662           14     8    2     8    HCC          Microarray
  9     GSE70880LC    0.880 (0.773--0.987)   \<0.001   20                     20                      8.210           16     2    4     18   LC           Microarray
  10    TCGA-BLCA     0.772 (0.679--0.866)   \<0.001   352                    15                      0.612           203    1    149   14   BLCA         RNA-seq
  11    TCGA-BRCA     0.978 (0.970--0.988)   \<0.001   1107                   100                     0.590           1045   7    62    93   BRCA         RNA-seq
  12    TCGA-CHOL     0.851 (0.738--0.964)   0.001     35                     9                       0.250           28     1    7     8    CHOL         RNA-seq
  13    TCGA-COAD     0.952 (0.923--0.982)   \<0.001   417                    14                      0.069           376    1    41    13   COAD         RNA-seq
  14    TCGA-ESCA     0.870 (0.763--0.977)   \<0.001   159                    9                       0.123           125    1    34    8    ESCA         RNA-seq
  15    TCGA-GBM      0.890 (0.754--1.000)   0.003     166                    5                       0.080           155    1    11    4    GBM          RNA-seq
  16    TCGA-HNSC     0.915 (0.871--0.960)   \<0.001   472                    18                      0.280           332    0    140   18   HNSC         RNA-seq
  17    TCGA-KICH     0.435 (0.302--0.568)   0.383     48                     22                      0.196           11     2    37    20   KICH         RNA-seq
  18    TCGA-KIRC     0.865 (0.823--0.908)   \<0.001   522                    64                      0.170           407    11   115   53   KIRC         RNA-seq
  19    TCGA-KIRP     0.653 (0.524--0.781)   0.019     153                    23                      0.025           144    14   9     9    KIRP         RNA-seq
  20    TCGA-LIHC     0.585 (0.510--0.660)   0.066     296                    45                      0.230           110    7    186   38   LIHC         RNA-seq
  21    TCGA-LUAD     0.909 (0.881--0.936)   \<0.001   532                    56                      0.443           427    5    105   51   LUAD         RNA-seq
  22    TCGA-LUSC     0.874 (0.829--0.919)   \<0.001   498                    48                      0.581           391    5    107   43   LUSC         RNA-seq
  23    TCGA-PRAD     0.537 (0.445--0.630)   0.405     410                    46                      1.026           403    39   7     7    PRAD         RNA-seq
  24    TCGA-READ     0.879 (0.761--0.997)   0.001     136                    7                       0.111           109    1    27    6    READ         RNA-seq
  25    TCGA-STAD     0.915 (0.869--0.961)   \<0.001   358                    18                      0.139           296    1    62    17   STAD         RNA-seq
  26    TCGA-THCA     0.867 (0.809--0.924)   \<0.001   473                    37                      0.093           380    5    93    32   THCA         RNA-seq
  27    TCGA-UCEC     0.596 (0.489--0.702)   0.083     343                    30                      0.232           240    14   103   16   UCEC         RNA-seq

AUC, area under the curve; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; CI, confidence interval; COAD, colon adenocarcinoma; CRC, colorectal cancer; ESCA, esophageal carcinoma; FN, false negative; FP, false positive; GBM, glioblastoma multiforme; GC, gastric cancer; HCC, hepatocellular cancer; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LC, lung cancer; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; RCC, renal cell carcinoma; READ, rectum adenocarcinoma; RNA-seq, RNA sequencing; SROC, summary receiver operating characteristic; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; TN, true negative; TP, true positive; UCEC, uterine corpus endometrial carcinoma; TCGA, The Cancer Genome Atlas.

###### 

Prognostic data for datasets in the meta-analysis.

  Dataset     Year   Country measure   Outcome   HR (95% CI)             P-value   Cut-off value   Type of cancer   No. of patients   Detection method
  ----------- ------ ----------------- --------- ----------------------- --------- --------------- ---------------- ----------------- ------------------
  GSE53622    2014   China             OS        1.474 (0.685--3.176)    0.321     8.548           ESCC             120               RNA-seq
  GSE53624    2014   China             OS        1.645 (0.900--3.006)    0.106     7.960           ESCC             238               RNA-seq
  TCGA-BLCA   2014   USA               OS        1.372 (1.006--1.873)    0.046     1.751           BLCA             352               RNA-seq
  TCGA-BRCA   2014   USA               OS        1.452 (1.034--2.040)    0.032     4.430           BRCA             1107              RNA-seq
  TCGA-CESC   2014   USA               OS        1.417 (0.735--2.734)    0.298     0.063           CESC             306               RNA-seq
  TCGA-COAD   2014   USA               OS        1.961 (1.281--3.000)    0.002     0.527           COAD             417               RNA-seq
  TCGA-ESCA   2014   USA               OS        1.777 (0.942--3.350)    0.076     0.126           ESCA             159               RNA-seq
  TCGA-GBM    2014   USA               OS        1.650 (1.131--2.409)    0.009     0.638           GBM              166               RNA-seq
  TCGA-HNSC   2014   USA               OS        1.338 (1.010--1.774)    0.043     1.891           HNSC             472               RNA-seq
  TCGA-KICH   2014   USA               OS        3.475 (0.720--16.774)   0.121     0.062           KICH             48                RNA-seq
  TCGA-KIRC   2014   USA               OS        1.344 (0.991--1.822)    0.057     0.372           KIRC             522               RNA-seq
  TCGA-KIRP   2014   USA               OS        3.678 (1.749--7.734)    0.001     0.095           KIRP             153               RNA-seq
  TCGA-LIHC   2014   USA               OS        1.322 (0.739--2.366)    0.347     0.046           LIHC             296               RNA-seq
  TCGA-LUAD   2014   USA               OS        1.561 (1.099--2.218)    0.013     0.590           LUAD             532               RNA-seq
  TCGA-LUSC   2014   USA               OS        1.330 (1.000--1.769)    0.050     1.370           LUSC             498               RNA-seq
  TCGA-MESO   2014   USA               OS        2.122 (1.269--3.548)    0.004     1.030           MESO             87                RNA-seq
  TCGA-PAAD   2014   USA               OS        2.519 (1.093--5.806)    0.030     0.442           PAAD             179               RNA-seq
  TCGA-PRAD   2014   USA               OS        0.676 (0.151--3.021)    0.608     0.074           PRAD             410               RNA-seq
  TCGA-READ   2014   USA               OS        1.807 (0.751--4.345)    0.186     1.040           READ             136               RNA-seq
  TCGA-STAD   2014   USA               OS        1.349 (0.973--1.869)    0.072     0.822           STAD             358               RNA-seq
  TCGA-SARC   2014   USA               OS        1.672 (1.112--2.516)    0.014     0.937           SARC             262               RNA-seq
  TCGA-SKCM   2014   USA               OS        1.207 (0.915--1.593)    0.183     0.462           SKCM             461               RNA-seq
  TCGA-THCA   2014   USA               OS        4.047 (1.403--11.673)   0.010     0.628           THCA             473               RNA-seq
  TCGA-UCEC   2014   USA               OS        1.128 (0.696--1.829)    0.624     0.147           UCEC             343               RNA-seq
  TCGA-THYM   2014   USA               OS        4.389 (0.908--21.214)   0.066     0.148           THYM             118               RNA-seq

BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; CI, confidence interval; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; ESCC, esophageal squamous cell carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; HR, hazard ratio; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OS, overall survival; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; RNA-seq, RNA sequencing; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma.

###### 

Subgroup analysis of overall survival based on primary tumors of different organ systems in the meta-analysis.

  Subgroup              No. of studies   No. of patients   Pooled HR (95% CI)     PHet    I^2^ (%)   P-value
  --------------------- ---------------- ----------------- ---------------------- ------- ---------- ---------
  Digestive system      8                1903              1.598 (1.321, 1.933)   0.813   0.0        \<0.001
  Urinary system        4                1075              1.491 (1.212, 1.833)   0.058   60.0       \<0.001
  Reproductive system   3                649               1.177 (0.808, 1.716)   0.650   0.0        0.396
  Respiratory system    2                1030              1.417 (1.136, 1.769)   0.488   0.0        0.002
  Soft tissue           2                349               1.833 (1.332, 2.524)   0.477   0.0        \<0.001
  Endocrine system      2                591               4.151 (1.723, 9.998)   0.933   0.0        0.002
  Breast                1                1107              1.452 (1.034, 2.039)   --      --         0.031
  Nervous system        1                166               1.650 (1.131, 2.408)   --      --         0.009
  Head and neck         1                472               1.338 (1.010, 1.773)   --      --         0.043
  Skin                  1                461               1.207 (0.915, 1.593)   --      --         0.183

The datasets in each subgroup are shown in [Fig. 4B](#f4-ol-0-0-11648){ref-type="fig"}. HR, hazard ratio; PHet, P-value for heterogeneity.

###### 

Association between LINC01614 and clinicopathological characteristics of patients with non-small cell lung cancer (n=74).

                                   LINC01614        
  --------------------------- ---- ----------- ---- -------
  Sex                                               0.104
    Male                      37   15          22   
    Female                    37   22          15   
  Age (years)                                       0.235
    ≤60                       14   5           9    
    \>60                      60   32          28   
  Size of tumor (cm)                                0.047
    ≤3                        24   16          8    
    \>3                       50   21          29   
  Lymph node metastasis                             0.032
    N0                        45   27          18   
    N1-3                      29   10          19   
  Degree of differentiation                         0.344
    Moderate-well             44   24          20   
    Poor                      30   13          17   
  Histological type                                 0.642
    Adenocarcinoma            36   19          17   
    Squamous carcinoma        38   18          20   
  Smoking                                           0.483
    Yes                       41   19          22   
    No                        33   18          15   
  TNM stage                                         0.016
    I                         35   23          12   
    II                        25   7           18   
    III/IV                    14   7           7    

The cutoff value for classification into high and low LINC01614 expression was based on the median of the relative expression levels of LINC01614. LINC01614, long intergenic non-coding RNA 1614; TNM, tumor-node-metastasis.

###### 

Association between LINC01614 and clinicopathological characteristics in patients with colorectal cancer (n=78).

                                   LINC01614        
  --------------------------- ---- ----------- ---- -------
  Sex                                               0.174
    Male                      40   17          23   
    Female                    38   22          16   
  Age (years)                                       0.645
    ≤60                       32   15          17   
    \>60                      46   24          22   
  T classification                                  0.098
    T1-2                      11   8           3    
    T3-4                      67   31          36   
  Lymph node metastasis                             0.006
    N0                        44   28          16   
    N1-2                      34   11          23   
  Distant metastasis                                0.069
    M0                        69   37          32   
    M1                        9    2           7    
  Degree of differentiation                         0.131
    Moderate-well             56   31          25   
    Poor                      22   8           14   
  Location                                          0.460
    Right                     32   15          17   
    Transverse                11   4           7    
    Left                      10   7           3    
    Sigmoid colon             25   13          12   
    TNM stage                                       0.022
    I/II                      44   27          17   
    III/IV                    34   12          22   

The cutoff value for classification into high and low LINC01614 expression was based on the median of the relative expression levels of LINC01614. LINC01614, long intergenic non-coding RNA 1614; TNM, tumor-node-metastasis.
